Denali therapeutics announces initiation of phase 2 study by partner sanofi of ripk1-inhibitor dnl758 (sar443122) in cutaneous lupus erythematosus (cle) patients

South san francisco, calif., june 28, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that its partner sanofi has commenced dosing in a phase 2 study of dnl758 (sar443122), a peripherally-restricted small molecule inhibitor of ripk1, in patients with cutaneous lupus erythematosus (cle).
DNLI Ratings Summary
DNLI Quant Ranking